|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004358,
umls-concept:C0004561,
umls-concept:C0024141,
umls-concept:C0087111,
umls-concept:C0205210,
umls-concept:C0229671,
umls-concept:C0333668,
umls-concept:C0439849,
umls-concept:C0441889,
umls-concept:C0767393,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1979963,
umls-concept:C2003903,
umls-concept:C2911692
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-6-16
|
|
pubmed:abstractText |
To assess the relationships between serum B lymphocyte stimulator (BLyS) levels, autoantibody profile and clinical response in patients with systemic lupus erythematosus (SLE) following rituximab-based B cell depletion therapy (BCDT).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Antinuclear,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Autoantibodies,
http://linkedlifedata.com/resource/pubmed/chemical/B-Cell Activating Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin M,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1468-2060
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1011-6
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17962238-Antibodies, Antinuclear,
pubmed-meshheading:17962238-Antibodies, Monoclonal,
pubmed-meshheading:17962238-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:17962238-Antirheumatic Agents,
pubmed-meshheading:17962238-Autoantibodies,
pubmed-meshheading:17962238-B-Cell Activating Factor,
pubmed-meshheading:17962238-B-Lymphocytes,
pubmed-meshheading:17962238-Follow-Up Studies,
pubmed-meshheading:17962238-Genes, Immunoglobulin Heavy Chain,
pubmed-meshheading:17962238-Humans,
pubmed-meshheading:17962238-Immunoglobulin G,
pubmed-meshheading:17962238-Immunoglobulin M,
pubmed-meshheading:17962238-Lupus Erythematosus, Systemic,
pubmed-meshheading:17962238-Lymphocyte Count,
pubmed-meshheading:17962238-Lymphocyte Depletion,
pubmed-meshheading:17962238-Recurrence,
pubmed-meshheading:17962238-Severity of Illness Index,
pubmed-meshheading:17962238-Time Factors,
pubmed-meshheading:17962238-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
|
|
pubmed:affiliation |
Centre for Rheumatology Research, Department of Medicine, 46 Cleveland St, London W1T 4JF, UK. g.cambridge@ucl.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
